

# Anti-HPV16 E1/E4 [TVG 402]

**Catalogue number:** 151171

**Sub-type:** Primary antibody

**Images:** [https://res.cloudinary.com/ximbio/image/upload/c\\_fit/bfea7968-03f7-458b-949d-55acbed6c54b.jpg](https://res.cloudinary.com/ximbio/image/upload/c_fit/bfea7968-03f7-458b-949d-55acbed6c54b.jpg)

## Contributor

**Inventor:**

**Institute:** University of Cambridge

**Images:** [https://res.cloudinary.com/ximbio/image/upload/c\\_fit/bfea7968-03f7-458b-949d-55acbed6c54b.jpg](https://res.cloudinary.com/ximbio/image/upload/c_fit/bfea7968-03f7-458b-949d-55acbed6c54b.jpg)

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-HPV16 E1/E4 [TVG 402]

**Alternate name:**

**Class:** Monoclonal

**Conjugate:** Unconjugated

**Description:** TVG 402 and TVG 403 were the first antibodies against HPV16 E1 & E4 and should complement those already available to E7 and L1 for the screening of frozen sections of clinical biopsies. They will be of value in monitoring the progress of HPV infection from benign lesions to invasive cancer.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:** IgG1

**Reactivity:** Human papilloma virus

**Selectivity:**

**Host:** Mouse

**Immunogen:** Antigen for hybridoma production was expressed as a b galactosidase fusion protein using the pEX expression system and was consequently cleaved to release the E1/E4 polypeptide.

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**

**Recommended controls:**

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:**

## Target details

**Target:** Human Papilloma Virus 16 early proteins 1 and 4 (HPV16 E1/E4)

**Target alternate names:**

**Target background:** The human papilloma virus (HPV) family of DNA tumor viruses includes HPV-16 and HPV-18, which are associated with a large proportion of cervical cancer case. E1 and E2 are proteins involved in the regulation of viral DNA replication. TVG 402 and TVG 403 were the first antibodies against HPV16 E1 & E4 and should complement those already available to E7 and L1 for the screening of frozen sections of clinical biopsies. They will be of value in monitoring the progress of HPV infection from benign lesions to invasive cancer.

**Molecular weight:** 10 kDa

**Ic50:**

## Applications

**Application:** ELISA ; IHC ; IP ; WB

**Application notes:**

## Handling

**Format:** Liquid

**Concentration:** 1 mg/ml

**Passage number:**

**Growth medium:**

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:** PBS with 0.02% azide

**Storage conditions:** -15° C to -25° C

**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:**

## References

**References:** Chen et al. 2020. Antiviral Res. 178:104794. PMID: 32298665. ; Kannan et al. 2017. Sci Rep. 7:46102. PMID: 28383029. ; Harris et al. 2013. Br J Cancer. 108(4):859-65. PMID: 23385729. ; Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein. ; Tommasino et al. 1993. Oncogene. 8(1):195-202. PMID: 8380917. ; HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A.

CancerTools.org